Control of cytokine mRNA degradation by the histone deacetylase inhibitor ITF2357 in rheumatoid arthritis fibroblast-like synoviocytes: beyond transcriptional regulation

被引:0
|
作者
Chiara Angiolilli
Pawel A. Kabala
Aleksander M. Grabiec
Marzia Rossato
Wi S. Lai
Gianluca Fossati
Paolo Mascagni
Christian Steinkühler
Perry J. Blackshear
Kris A. Reedquist
Dominique L. Baeten
Timothy R. D. J. Radstake
机构
[1] University Medical Center Utrecht,Laboratory of Translational Immunology and Department of Rheumatology and Clinical Immunology
[2] Academic Medical Center/University of Amsterdam,Amsterdam Rheumatology and Immunology Center, Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology
[3] Jagiellonian University,Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology
[4] University of Verona,Functional Genomics Center
[5] National Institute of Environmental Health Sciences,Signal Transduction Laboratory
[6] Italfarmaco Research and Development,undefined
关键词
Rheumatoid arthritis; Fibroblast-like synoviocytes; Inflammation; mRNA stability; Tristetraprolin; Histone deacetylase inhibitor; ITF2357;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 50 条
  • [1] Control of cytokine mRNA degradation by the histone deacetylase inhibitor ITF2357 in rheumatoid arthritis fibroblast-like synoviocytes: beyond transcriptional regulation
    Angiolilli, Chiara
    Kabala, Pawel A.
    Grabiec, Aleksander M.
    Rossato, Marzia
    Lai, Wi S.
    Fossati, Gianluca
    Mascagni, Paolo
    Steinkuhler, Christian
    Blackshear, Perry J.
    Reedquist, Kris A.
    Baeten, Dominique L.
    Radstake, Timothy R. D. J.
    ARTHRITIS RESEARCH & THERAPY, 2018, 20
  • [2] CONTROL OF CYTOKINE MRNA DEGRADATION BY THE HISTONE DEACETYLASE INHIBITOR ITF2357 IN RHEUMATOID ARTHRITIS FIBROBLAST-LIKE SYNOVIOCYTES
    Angiolilli, C.
    Kabala, P.
    Grabiec, A.
    Rossato, M.
    Lai, W.
    Blackshear, P.
    Reedquist, K.
    Baeten, D.
    Radstake, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 878 - 879
  • [3] Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Induces Apoptosis in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
    Chen, Hui
    Pan, Jing
    Wang, Jin-dan
    Liao, Qiu-mei
    Xia, Xiao-ru
    INFLAMMATION, 2016, 39 (01) : 39 - 46
  • [4] Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Induces Apoptosis in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
    Hui Chen
    Jing Pan
    Jin-dan Wang
    Qiu-mei Liao
    Xiao-ru Xia
    Inflammation, 2016, 39 : 39 - 46
  • [5] Decreased whole blood cytokine production during a phase I trial of the histone deacetylase inhibitor ITF2357
    Oldoni, Tiziano
    Furlan, Antonio
    Monzani, M. Valmen
    Dinarello, Charles A.
    CYTOKINE, 2009, 48 (1-2) : 120 - 120
  • [6] The role of histone deacetylases in rheumatoid arthritis fibroblast-like synoviocytes
    Hawtree, Sarah
    Muthana, Munitta
    Wilson, Anthony G.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2013, 41 : 783 - 788
  • [7] The oral histone deacetylase inhibitor ITF2357 reduces cytokine production, cytokine activities and protects islet β-cells in vivo and in vitro
    Lewis, Eli C.
    Blaabjerg, Lykke
    Storling, Joachim
    Ronn, Sif G.
    Mascagni, Paolo
    Dinarello, Charles A.
    Mandrup-Poulsen, Thomas
    CYTOKINE, 2009, 48 (1-2) : 92 - 93
  • [8] Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes
    Angiolilli, Chiara
    Kabala, Pawel A.
    Grabiec, Aleksander M.
    Van Baarsen, Iris M.
    Ferguson, Bradley S.
    Garcia, Samuel
    Fernandez, Beatriz Malvar
    McKinsey, Timothy A.
    Tak, Paul P.
    Fossati, Gianluca
    Mascagni, Paolo
    Baeten, Dominique L.
    Reedquist, Kris A.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) : 277 - 285
  • [9] Safety and efficacy of ITF2357, an orally active histone deacetylase inhibitor in the treatment of systemic onset juvenile idiopathic arthritis
    Vojinovic, J.
    Damjanov, N.
    Furlan, A.
    D'Urzo, C.
    Susic, G.
    Pasic, S.
    Iagaru, N.
    Stefan, M.
    Dinarello, C. A.
    CYTOKINE, 2010, 52 (1-2) : 24 - 24
  • [10] Pharmacokinetics, Safety and Inducible Cytokine Responses during a Phase 1 Trial of the Oral Histone Deacetylase Inhibitor ITF2357 (Givinostat)
    Antonio Furlan
    Valmen Monzani
    Leonid L Reznikov
    Flavio Leoni
    Gianluca Fossati
    Daniela Modena
    Paolo Mascagni
    Charles A Dinarello
    Molecular Medicine, 2011, 17 : 353 - 362